Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
International Sweetene...International Sweetener Colloquium
Not Confirmed
Not Confirmed
22-25 February, 2026
Not Confirmed
Not Confirmed
23-25 February, 2026
Clinical Trial Supply ...Clinical Trial Supply Europe
Not Confirmed
Not Confirmed
24-25 February, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
International Sweetene...International Sweetener Colloquium
Industry Trade Show
Not Confirmed
22-25 February, 2026
Industry Trade Show
Not Confirmed
23-25 February, 2026
Clinical Trial Supply ...Clinical Trial Supply Europe
Industry Trade Show
Not Confirmed
24-25 February, 2026
Digital content

04 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/04/3231962/37519/en/Akebia-Therapeutics-to-Present-at-the-Guggenheim-Emerging-Outlook-Biotech-Summit-2026.html

02 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/02/3230600/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

12 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/12/3216827/37519/en/Akebia-Therapeutics-Announces-Corporate-Updates-and-2026-Pipeline-Outlook.html

06 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/06/3213549/37519/en/Akebia-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-Praliciguat-for-the-Treatment-of-Focal-Segmental-Glomerulosclerosis-FSGS.html

05 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/05/3213185/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

01 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/01/3197426/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
ABOUT THIS PAGE